c-Myc and Downstream Targets in the Pathogenesis and Treatment of Cancer

E-ISSN： 2212-3970|1|3|305-326

ISSN： 1574-8928

Source： Recent Patents on Anti-Cancer Drug Discovery, Vol.1, Iss.3, 2006-11, pp. : 305-326

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

C-MYC modulation induces responsiveness to paclitaxel in adrenocortical cancer cell lines

International Journal of Oncology, Vol. 46, Iss. 5, 2015-01 ,pp. : 2231-2240

Spandidos Publications

Access to resources Recommend Favorite

Combination Antigene Therapy Targeting c-myc and c-erbB 2 in the Ovarian Cancer COC 1 Cell Line

By Fei R. Shaoyang L.

Gynecologic Oncology, Vol. 85, Iss. 1, 2002-04 ,pp. : 40-44

Elsevier

Access to resources Recommend Favorite

bcl-2 expression is reciprocal to p53 and c-myc expression in metastatic human colorectal cancer

By Popescu R.A. Lohri A. de Kant E. Thiede C. Reuter J. Herrmann R. Rochlitz C.F.

European Journal of Cancer, Vol. 34, Iss. 8, 1998-07 ,pp. : 1268-1273

Elsevier

Access to resources Recommend Favorite

c-Myc down-regulation is involved in proteasome inhibitor-mediated enhancement of radiotherapeutic efficacy in non-small cell lung cancer

By Jung Joohee Kim Eun-Jin Chung Hye Kyung Park Heon Joo Jeong Seong-Yun Choi Eun Kyung

International Journal of Oncology, Vol. 40, Iss. 2, 2012-02 ,pp. : 385-390

Spandidos Publications

Access to resources Recommend Favorite

Suppression of C-myc Expression Associates with Anti-Proliferation of Aloe-Emodin on Gastric Cancer Cells

By Guo Junming Xiao Bingxiu Liu Qiong Gong Zhaohui Le Yanping

Cancer Investigation, Vol. 26, Iss. 4, 2008-05 ,pp. : 369-374

Informa Healthcare

Access to resources Recommend Favorite